The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
PEG−Doxorubicin Conjugates: Influence of Polymer Structure on Drug Release, in Vitro Cytotoxicity, Biodistribution, and Antitumor Activity
Abstract
Polymer-drug conjugates (polymer therapeutics) are finding increasing use as novel anticancer agents. Here a series of poly(ethylene glycol) PEG-doxorubicin (Dox) conjugates were synthesized using polymers of linear or branched architecture (molecular weight 5000-20000 g/mol) and with different peptidyl linkers (GFLG, GLFG, GLG, GGRR, and RGLG). The resultant conjugates had a drug loading of 2.7-8.0 wt % Dox and contained <2.0% free drug (% total drug). All conjugates containing a GFLG linker showed approximately 30% release of Dox at 5 h irrespective of PEG molecular weight or architecture. The GLFG linker was degraded more quickly (approximately 57% Dox release at 5 h), and the other linkers more slowly (<16% release at 5 h), by lysosomal enzymes in vitro. In vitro there was no clear relationship between cytotoxicity toward B16F10 cells and the observed Dox release rate. All PEG conjugates were more than 10-fold less toxic (IC50 values > 2 microg/mL) than free Dox (IC50 value = 0.24 microg/mL). Biodistribution in mice bearing sc B16F10 tumors was assessed after administration of PEGs (5000, 10000, or 20000 g/mol) radioiodinated using the Bolton and Hunter reagent or PEG-Dox conjugates by HPLC. The 125I-labeled PEGs showed a clear relationship between Mw and blood clearance and tumor accumulation. The highest Mw PEG had the longest plasma residence time and consequently the greatest tumor targeting. The PEG-Dox conjugates showed a markedly prolonged plasma clearance and greater tumor targeting compared to free Dox, but there was no clear molecular weight-dependence on biodistribution. This was consistent with the observation that the PEG-Dox conjugates formed micelles in aqueous solution comprising 2-20 PEG-Dox molecules depending on polymer Mw and architecture. Although PEG-Dox showed greater tumor targeting than free Dox, PEG conjugation led to significantly lower anthracycline levels in heart. Preliminary experiments to assess antitumor activity against sc B16F10 in vivo showed the PEG5000linear (L)-GFLG-Dox and PEG10000branched (B)-GLFG-Dox (both 5 mg/kg Dox-equiv) to be the most active with T/C values of 146 and 143%, respectively. Free Dox did not show significant activity in this model (T/C = 121%). Dose escalation of PEG5000(L)-GFLG-Dox to 10 mg/kg Dox-equiv prolonged further animal survival (T/C = 161%). Using the Dox-sensitive model ip L1210 (where Dox displayed a T/C = 150% after single ip dose), the PEG5000(L)-GFLG-Dox displayed a maximum T/C of 141% (10 mg/kg Dox-equiv) using a once a day (x3) schedule. Further studies are warranted with PEG5000(L)-GFLG-Dox to determine its spectrum of antitumor activity and also the optimum dosing schedule before clinical testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Self-citationLight scattering and the absolute characterization of macromolecules
Wyatt, P. J. (1993) · Analytica Chimica Acta · doi:10.1016/0003-2670(93)80373-s · Cited by 1,436
Effective drug delivery by PEGylated drug conjugates
Greenwald, R. B., Choe, Y. H., McGuire, J., & Conover, C. D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00180-1 · Cited by 869
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Self-citationDrug-polymer conjugates: potential for improved chemotherapy
Duncan, R. (1992) · Anti-Cancer Drugs · doi:10.1097/00001813-199206000-00001 · Cited by 444
Self-citationSeymour, L. W., Duncan, R., Strohalm, J., & Kopeček, J. (1987) · Journal of Biomedical Materials Research · doi:10.1002/jbm.820211106 · Cited by 436
Self-citationHepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435
A Branched Monomethoxypoly(ethylene glycol) for Protein Modification
Monfardini, C., Schiavon, O., Caliceti, P., Morpurgo, M., Harris, J. M., & Veronese, F. M. (1995) · Bioconjugate Chemistry · doi:10.1021/bc00031a006 · Cited by 257
Self-citationSgouras, D., & Duncan, R. (1990) · Journal of Materials Science: Materials in Medicine · doi:10.1007/bf00839070 · Cited by 234
Self-citation
Cited by
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Enzyme-responsive nanoparticles for drug release and diagnostics
de la Rica, R., Aili, D., & Stevens, M. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.002 · Cited by 765
State of the art in PEGylation: The great versatility achieved after forty years of research
Pasut, G., & Veronese, F. M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.037 · Cited by 720
Self-citationPEG — A versatile conjugating ligand for drugs and drug delivery systems
Kolate, A., Baradia, D., Patil, S., Vhora, I., Kore, G., & Misra, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.046 · Cited by 648
Polymer–drug conjugation, recent achievements and general strategies
Pasut, G., & Veronese, F. M. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.008 · Cited by 616
Self-citationPolymer Architecture and Drug Delivery
Qiu, L. Y., & Bae, Y. H. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-9046-2 · Cited by 604
Vitamin E TPGS as a molecular biomaterial for drug delivery
Zhang, Z., Tan, S., & Feng, S.-S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.046 · Cited by 586
Andrew MacKay, J., Chen, M., McDaniel, J. R., Liu, W., Simnick, A. J., & Chilkoti, A. (2009) · Nature Materials · doi:10.1038/nmat2569 · Cited by 580
Shen, Y., Jin, E., Zhang, B., Murphy, C. J., Sui, M., Zhao, J., Wang, J., Tang, J., Fan, M., Van Kirk, E., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja909475m · Cited by 565
Biodistribution, Clearance, and Long‐Term Fate of Clinically Relevant Nanomaterials
Bourquin, J., Milosevic, A., Hauser, D., Lehner, R., Blank, F., Petri‐Fink, A., & Rothen‐Rutishauser, B. (2018) · Advanced Materials · doi:10.1002/adma.201704307 · Cited by 461
Lee, E. S., Oh, K. T., Kim, D., Youn, Y. S., & Bae, Y. H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.08.006 · Cited by 446
UV and Near-IR Triggered Release from Polymeric Nanoparticles
Fomina, N., McFearin, C., Sermsakdi, M., Edigin, O., & Almutairi, A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102595j · Cited by 362
Engineered polymers for advanced drug delivery
Kim, S., Kim, J.-H., Jeon, O., Kwon, I. C., & Park, K. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.021 · Cited by 355
Designing Smart Polymer Conjugates for Controlled Release of Payloads
Seidi, F., Jenjob, R., & Crespy, D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00006 · Cited by 316
Administration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
Anticancer Polymeric Nanomedicines
Tong, R., & Cheng, J. (2007) · Polymer Reviews · doi:10.1080/15583720701455079 · Cited by 310
Oxime Linkage: A Robust Tool for the Design of pH-Sensitive Polymeric Drug Carriers
Jin, Y., Song, L., Su, Y., Zhu, L., Pang, Y., Qiu, F., Tong, G., Yan, D., Zhu, B., & Zhu, X. (2011) · Biomacromolecules · doi:10.1021/bm200956u · Cited by 216
Ke, X., Ng, V. W. L., Ono, R. J., Chan, J. M. W., Krishnamurthy, S., Wang, Y., Hedrick, J. L., & Yang, Y. Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.061 · Cited by 146
Metadata
- Authors
- Veronese, F. M., Schiavon, O., Pasut, G., Mendichi, R., Andersson, L., Tsirk, A., Ford, J., Wu, G., Kneller, S., Davies, J., & Duncan, R.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-05-14
- Volume
- 16
- Issue
- 4
- Pages
- 775-784
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W2087842405
- Cited by
- 282
- References
- 15
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.